Accord Seeks To Capitalize On Portfolio And Partnerships
Company Points To Growth That Outperforms Peers
Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.
